Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
180 stocks in the Americas match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| MSCL.TO | Satellos Bioscience Inc. | Rare disease | $199.95M | 13.08 CAD | −31.09% | −2.10% |
| PLX | Protalix BioTherapeutics, Inc. | Rare disease | $199.82M | $2.48 | −22.26% | +6.44% |
| MSLE | Satellos Bioscience Inc. | Rare disease | $198.59M | $9.36 | −30.12% | −1.06% |
| SPRB | Spruce Biosciences, Inc. |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| Rare disease |
| $176.69M |
| $61.48 |
| −74.38% |
| +47.79% |
| MDWD | MediWound Ltd. | Rare disease | $163.96M | $12.70 | −37.44% | −13.13% |
| EQ | Equillium, Inc. | Rare disease | $149.64M | $2.36 | −33.33% | +1.72% |
| AARD | Aardvark Therapeutics, Inc. | Rare disease | $149.04M | $6.81 | −62.04% | +6.07% |
| UNCY | Unicycive Therapeutics, Inc. | Rare disease | $148.74M | $5.43 | −37.87% | +9.92% |
| MIST | Milestone Pharmaceuticals Inc. | Rare disease | $146.91M | $1.18 | −61.44% | +10.28% |
| INO | Inovio Pharmaceuticals, Inc. | Rare disease | $134.42M | $1.30 | −56.38% | +26.21% |
| CPIX | Cumberland Pharmaceuticals Inc. | Rare disease | $130.35M | $8.97 | −3.34% | +69.86% |
| RFL | Rafael Holdings, Inc. | Rare disease | $119.08M | $2.29 | −42.17% | +9.05% |
| MDP.TO | Medexus Pharmaceuticals Inc. | Rare disease | $117.29M | 5.18 CAD | −5.82% | +7.02% |
| PYPD | PolyPid Ltd. | Rare disease | $103.79M | $5.11 | −10.82% | +36.27% |
| PTHS | Pelthos Therapeutics Inc. | Rare disease | $102.53M | $26.78 | −28.59% | −3.56% |
| FBIO | Fortress Biotech, Inc. | Rare disease | $94.38M | $2.81 | −37.97% | −17.11% |
| PLYX | Polaryx Therapeutics, Inc. | Rare disease | $94.21M | $2.09 | −95.73% | +5.03% |
| RLYB | Rallybio Corporation | Rare disease | $89.64M | $16.88 | −3.95% | +4.49% |
| GOSS | Gossamer Bio, Inc. | Rare disease | $85.01M | $0.17 | −95.51% | −15.17% |
| TELO | Telomir Pharmaceuticals, Inc. | Rare disease | $80.47M | $1.17 | −44.05% | −0.85% |
| TENX | Tenax Therapeutics, Inc. | Rare disease | $79.34M | $2.12 | −89.07% | −86.58% |
| FBIOP | Fortress Biotech, Inc. | Rare disease | $71.45M | $18.40 | −14.14% | −1.92% |
| SPRO | Spero Therapeutics, Inc. | Rare disease | $71.05M | $1.22 | −60.39% | +2.09% |
| RNTX | Rein Therapeutics Inc. | Rare disease | $69.01M | $0.80 | −63.30% | +2.30% |
| IMA | ImageneBio, Inc. | Rare disease | $61.64M | $5.43 | −62.13% | −5.73% |
| SCYX | SCYNEXIS, Inc. | Rare disease | $56.41M | $5.67 | −7.83% | +56.20% |
| ATYR | aTyr Pharma, Inc. | Rare disease | $54.05M | $0.55 | −91.52% | +11.54% |
| NSRX | Nasus Pharma Ltd. | Rare disease | $48.01M | $4.05 | −59.46% | +33.66% |
| MCRB | Seres Therapeutics, Inc. | Rare disease | $47.81M | $4.76 | −84.12% | −0.83% |
| EDSA | Edesa Biotech, Inc. | Rare disease | $47.63M | $4.94 | −75.69% | −0.60% |
| GRCE | Grace Therapeutics, Inc. | Rare disease | $46.28M | $2.15 | −58.49% | −4.44% |
| MREO | Mereo BioPharma Group plc | Rare disease | $44.39M | $0.28 | −88.27% | −10.03% |
| NNVC | NanoViricides, Inc. | Rare disease | $32.68M | $1.28 | −42.60% | −20.50% |
| QNCX | Quince Therapeutics, Inc. | Rare disease | $31.84M | $31.31 | −31.19% | +61.64% |
| BRNS | Barinthus Biotherapeutics plc | Rare disease | $28.86M | $0.71 | −61.40% | +23.93% |
| RVX.TO | Resverlogix Corp. | Rare disease | $24.81M | 0.10 CAD | −33.33% | 0.00% |
| JSPR | Jasper Therapeutics, Inc. | Rare disease | $23.96M | $0.72 | −76.46% | +13.43% |
| TVRD | Tvardi Therapeutics, Inc. | Rare disease | $23.74M | $1.78 | −95.92% | −27.05% |
| COCP | Cocrystal Pharma, Inc. | Rare disease | $21.57M | $1.12 | −58.05% | +20.43% |
| VYNE | VYNE Therapeutics Inc | Rare disease | $19.07M | $28.56 | −39.17% | +3080.40% |
| KTTA | Pasithea Therapeutics Corp. | Rare disease | $19.05M | $0.57 | −72.33% | +26.67% |
| CALC | CalciMedica, Inc. | Rare disease | $18.06M | $0.59 | −91.84% | −18.18% |
| CMMB | Chemomab Therapeutics Ltd. | Rare disease | $16.85M | $2.59 | −37.14% | +81.12% |
| HIND | Vyome Holdings, Inc. | Rare disease | $15.16M | $2.16 | −82.00% | +8.54% |
| AZTR | Azitra, Inc. | Rare disease | $10.48M | $0.17 | −87.65% | +33.00% |
| QNRX | Quoin Pharmaceuticals, Ltd. | Rare disease | $10.40M | $5.18 | −87.61% | +23.33% |
| IMRN | Immuron Limited | Rare disease | $9.20M | $1.14 | −52.30% | +4.11% |
| SNGX | Soligenix, Inc. | Rare disease | $8.36M | $0.38 | −88.84% | +6.67% |
| XCUR | Exicure, Inc. | Rare disease | $8.25M | $1.26 | −86.71% | −27.59% |
| INM | InMed Pharmaceuticals Inc. | Rare disease | $7.64M | $1.43 | −42.80% | −14.37% |
| PULM | Pulmatrix, Inc. | Rare disease | $5.57M | $1.53 | −72.26% | −9.23% |
| CVKD | Cadrenal Therapeutics, Inc. | Rare disease | $4.80M | $1.55 | −89.41% | −22.89% |
| JAGX | Jaguar Health, Inc. | Rare disease | $4.78M | $0.92 | −98.92% | −4.63% |
| GLMD | Galmed Pharmaceuticals Ltd. | Rare disease | $4.48M | $4.33 | −20.55% | +710.86% |
| GRI | GRI Bio, Inc. | Rare disease | $4.28M | $1.91 | −97.62% | +33.57% |
| XRTX | XORTX Therapeutics Inc. | Rare disease | $4.03M | $2.22 | −68.54% | +8.20% |
| SXTP | 60 Degrees Pharmaceuticals, Inc. | Rare disease | $3.80M | $1.08 | −87.47% | −28.00% |
| MTNB | Matinas BioPharma Holdings, Inc. | Rare disease | $2.89M | $0.20 | −91.24% | −32.97% |
| APLI.TO | Appili Therapeutics Inc. | Rare disease | $1.44M | 0.02 CAD | −62.50% | +50.00% |
| VBIO | Valion Bio, Inc. | Rare disease | $647.60K | $0.16 | −95.30% | −45.83% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.